Transcript PowerPoint 簡報

Reasons to Choose Taiwan
UBI Asia in Partnership with UBI
Chang Yi Wang, PhD
Founder, UBI
Chairperson, UBI Asia
Core Technology
Molecular
Design of
Functional
Antigens
Adjuvant &
Formulation
Technologies
UBI / UBI Asia
Antigenic
Functional
Antigenics
Synthetic
Peptide
Technologies
Combinatorial
Library
UBITh ®
Technology
Antibody
Deimmunization
Immunodiagnostics
Vaccines and
Immunotherapeutics
Therapeutic
Monoclonal
Antibodies
Product Portfolios
Vaccines & Immunotherapeutics
SARS Vaccine
& Diagnostics
Canine Allergy
Therapeutic
FMDV
Vaccine &
Diagnostics
LHRH Vaccine
as Pet Contraceptive
LHRH Vaccine
for Boar Taint Removal &
Growth Promotion
Animal Health Products
Allergy
Therapeutic
HIV/AIDS
Vaccine & Therapeutic
LHRH Vaccine
as Prostate Cancer
Therapeutic
Alzheimer Disease
Therapeutic
Functional
Antigenics
Human Health Products
Business partners and Product
Development Sponsors of UBI








Division of AIDS, NIAID, NIH, USA [HIV
Immunotherapeutics]
NIAID, NIH, USA [Allergy Immunotherapeutic]
NCI, NIH, USA [Prostate Cancer Immunotherapeutic]
Baxter, USA
BioMerieux (Lyon, France), formerly Organon
Teknika of Akzo Nobel (Boxtel, Netherlands)
Merial (Lyon, France) (JV of Merck and Aventis,
largest animal health company in the world)
The United Laboratories (Zhuhai, China)
China Animal Husbandry Industry Corp. (Beijing,
China)
Synergy: Traditional Pharma / Innovative Bio
Pharmaceutics
Foundation in Taiwan
cGMP
Roche
Peptide Pilot
Plant
Protein Drug
Pilot Plant
GSK
Toll Manufacture
BioPharmaceutics
Foundation in
Taiwan
Biologics
Manufacture Plant
Specialty
Injectables
Compliance with FDA
International
BioPharmaceutics
Company
Business Model
Survival
cGMP
Pharmaceutical
Plants
Synergy
Pharma / Bio
Synergy
UBI / UBI Asia
rowth
Survival: Conservative Nurtures High Risk
UBI
技術轉移
UBI Asia
技術承接 &
產品創新研發
cGMP
Manufacture
•Acquire Roche & GSK cGMP plants:
Chemical drugs, Biologics
1999
2002
Innovative
R&D
•Peptide based:
Vaccine & diagnostics
•Protein based:
Therapeutic monoclonal
antibodies
UBI
Asia
FMDV Vaccine: Ko-T Con ® 口蹄安
FMDV Diagnostics
From Genomics to Products
Innovation Through Design
The Vision:
Complete Replacement of Traditional Vaccines
within 5 Years !!
UBI
Asia
UBITh® LHRH Immunotherapeutic
Boar Taint Removal Vaccine: Bota Con ® 寶特康
Pet Contraceptive Vaccine
Human Prostate Cancer Therapeutic
From Genomics to Products
Innovation Through Design
BotaCon ®寶特康:
An Immunotherapeutic to eliminate Boar Taint and
promote pig growth and
Cattle
UBI
Asia
Therapeutic Monoclonal Antibodies
Monoclonal Antibody Engineering
Monoclonal Antibody Humanization (Murine Ab to Human Ab)
1986
1975
1994
Fv
Fc
Hybridoma,
Cesar Milstein &
Georges Kohler
Chimeric mAb, Genentech CDR grafting, PDL
RePro, 1994, 447 M USD
OKT3, 1986, 55 M USD
Identification of
T cell and B cell
antigenic epitopes in
Variable regions
Rituxan, 1997, 298 M USD
1998
Deimmunization, Biovation
Well-Characterized Monoclonal Antibody (B4)
directed against HIV receptor complex for
treatment of HARRT resistant AIDS patients
through entry inhibition
UBI Asia provides services to and collaborates
with multiple commercial and research institutes
聯亞研發中心
UBI Asia
R&D
產程發展 &
原料藥生產
先導工廠
聯亞生產中心
配方研發
臨床試驗
產品登記
聯亞
cGMP廠
西藥 &
生技藥品
劑型生產
Vision: Designer Immunological Products
for the treatment, prevention, and diagnosis of
globally significant diseases
美國、美洲
UBI Asia
UBI國際
臨床&事業 研發&生產
中心
中心
台
灣
Synergy: UBI Asia / UBI
Basic
Research
Field &
Clinical Trials
Process
Development
Reasons to Choose Taiwan
UBI Asia in Partnership with UBI
•
•
•
•
•
•
Taiwan government with policies to promote
biotechnology
Taiwan has diligent, entrepreneurial and well-educated
human resources
Operations can be cost effective when compared with
the west
Easy access to fast breaking first hand business
information
Access to huge China market due to similarity in
language and cultural background
Training and testing ground for worldmarket due to its
extensive connections to the western world
Join us, and
Welcome to Taiwan!